However, the clinical predictive factors that indicate the response or resistance to anti-EGFR therapy should be identified before beginning such a treatment in patients with CRC to prevent drug-induced toxicity and avoid unnecessary expenses. This evidence concerns the gene EGFR and colorectal carcinoma.